Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil.

Autor: Queiroz MM; Oncology Center, Hospital Sírio-Libanês, Street Dona Adma Jafet, number 115, zip-code 01308-050, São Paulo, SP, Brazil. Electronic address: mmqueiroz93@gmail.com., Sacardo KP; Oncology Center, DASA, Av. das Nações Unidas, number 7815, zip-code 05425-070, São Paulo, SP, Brazil., Ribeiro MF; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 610 University Ave, zip-code ON M5G 2C1, Toronto, ON, Canada., Gadotti LL; Oncology Center, Hospital Sírio-Libanês, Street Dona Adma Jafet, number 115, zip-code 01308-050, São Paulo, SP, Brazil., Saddi R; Oncology Center, Hospital Sírio-Libanês, Street Dona Adma Jafet, number 115, zip-code 01308-050, São Paulo, SP, Brazil., Oliveira LJC; Oncology Center, Oncoclínicas, Av. Brg. Faria Lima, number 4300, zip-code 04538-132, São Paulo, SP, Brazil., Linck RDM; Oncology Center, Hospital Sírio-Libanês, Street Dona Adma Jafet, number 115, zip-code 01308-050, São Paulo, SP, Brazil., Cruz MRS; Oncology Center, Hospital Sírio-Libanês, Street Dona Adma Jafet, number 115, zip-code 01308-050, São Paulo, SP, Brazil., Barroso-Sousa R; Oncology Center, DASA, Street Arariba, number 5, zip-code 71927-360, Brasília, DF, Brazil., Sahade M; Oncology Center, Hospital Sírio-Libanês, Street Dona Adma Jafet, number 115, zip-code 01308-050, São Paulo, SP, Brazil., Correa TS; Oncology Center, Hospital Sírio-Libanês, Street SSGAS 613, number 70.200, zip-code 70200-730, Brasília, DF, Brazil., Mano MS; Oncology Center, Oncoclínicas, Av. Brg. Faria Lima, number 4300, zip-code 04538-132, São Paulo, SP, Brazil., Suzuki DA; Oncology Center, Hospital Sírio-Libanês, Street SSGAS 613, number 70.200, zip-code 70200-730, Brasília, DF, Brazil., Shimada AK; Oncology Center, Hospital Sírio-Libanês, Street Dona Adma Jafet, number 115, zip-code 01308-050, São Paulo, SP, Brazil., Katz A; Oncology Center, Hospital Sírio-Libanês, Street Dona Adma Jafet, number 115, zip-code 01308-050, São Paulo, SP, Brazil.
Jazyk: angličtina
Zdroj: Cancer treatment and research communications [Cancer Treat Res Commun] 2023; Vol. 35, pp. 100683. Date of Electronic Publication: 2023 Jan 19.
DOI: 10.1016/j.ctarc.2023.100683
Abstrakt: Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have been recently developed and introduced into clinical practice.
Methods: We retrospectively analyzed data from patients with confirmed HR+/HER2 metastatic breast cancer treated with hormonal therapy in combination with ribociclib (R), palbociclib (P), or abemaciclib (A).
Outcomes: median progression-free survival (mPFS), time to treatment discontinuation (mTTD), and objective response rate (ORR).
Results: Between January 2016 - June 2021, 142 patients were treated with an CDK4/6i (79 P, 42 R, 21 A). The median age was 59 years and 67.6% had recurrent disease. Roughly 35.2%, 36.6%, 28.2% of the patients had 1, 2 or 3+ metastatic sites, respectively, and 55.6% of the patients received CDK4/6i as a first-line treatment. The mPFS was 28m(R) vs. 14m(P) vs. 6m(A) (P = 0.002), with a higher proportion of patients receiving R in the first-line setting. However, no difference was seen when the analysis was restricted to the first-line scenario (P = 0.193). Sixty-four patients required one dose reduction, and 19 patients required two. ORR was 76.2% (R) vs 62% (P) vs 42.9% (A). More patients achieved a complete response with R and P, with no difference in the incidence of partial response and stable disease. Adverse events occurred in 94.4% of the population, with the most common grade 3-4 AE being neutropenia (59.1%).
Conclusions: Our results confirm the efficacy and tolerability of CDK4/6i in routine clinical practice. This is the first real-world data describing and comparing the efficacy and toxicity of CDK4/6i in the Brazilian population.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Authors MMQ, RS, LJCO, and AK have no conflicts to declare. Author KPS reported consultant fees from Eurofarma and as a speaker from Novartis, AstraZeneca, Janssen, Lilly. Author MFR received honoraria from Bristol-Myers-Squibb. Author LLG reported receiving speaker bureau fees from the companies Novartis, AstraZeneca. Author RDML participates in clinical studies sponsored by the company Daiichi-Sankyo, Lilly, Roche, MSD, Bayer, GSK, Pfizer; as a speaker for AstraZeneca, Daiichi-Sankyo, Novartis, Pfizer, MSD, Lilly, Zodiac, United Medical, Grunenthal, Roche; participated in scientific events for the companies Lilly, Novartis, Roche, Fleury, Daiichi-Sankyo, Pfizer. Author MRSC reported receiving advisory board and presentations fees from Roche, AstraZeneca, Pfizer, MSD, Lilly, Gilead, BMS, Agendia, Janssen, Sanofi. Author RBS reported receiving speaker bureau fees from Agilant, AstraZeneca, Daichi-Sankyo, Eli Lilly, Pfizer, Novartis, Merck, Libbs and Roche; he has also served as a consultant/ advisor for AstraZeneca, Daichi-Sankyo, Eli Lilly, Libbs, Roche, Merck and has received support for attending medical conferences from AstraZeneca, Eli Lilly, Daichi-Sankyo, and Merck. Author MS reported consultant fees from MSD, Pfizer, AstraZeneca, Daiichi-Sankyo and Novartis. Author TSC participates in clinical studies sponsored by the company Lilly, Pfizer, Novartis, BMS; and reported receiving speaker bureau fees from AstraZeneca, Novartis, Pfizer, Novartis, Libs. Author MSM declares advisory engagements, presentations and educational expenses for Pfizer, Lilly and Novartis. DAS participates in clinical studies sponsored by the company Lilly, as a speaker at events for AstraZeneca, MSD, Novartis, Roche, Pfizer, Advisory, GSK, Roche; board advisory for Gilead. AKS participates as a sub investigator in clinical studies sponsored by the company Pfizer, Lilly, MSD, AstraZeneca, Novartis, Roche; as a speaker for Pfizer, Novartis, Lilly, AstraZeneca, Daiichi-Sankyo, MSD, Roche, Janssen, Amgen, Grunenthal.
(Copyright © 2023. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: